• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

莫洛替尼与帕西替尼治疗骨髓纤维化患者安全性及贫血转归的间接治疗比较

Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis.

作者信息

Masarova Lucia, Verstovsek Srdan, Palandri Francesca, Mesa Ruben, Harrison Claire, Dobi Balázs, Gorsh Boris, Wang Zhaohui, Ellis Catherine, Patnaik Dwaipayan, Liu Tom, Kapetanakis Venediktos

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

出版信息

Future Oncol. 2025 Jul;21(16):2067-2075. doi: 10.1080/14796694.2025.2511562. Epub 2025 Jun 6.

DOI:10.1080/14796694.2025.2511562
PMID:40476686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12218468/
Abstract

AIM

To perform an indirect treatment comparison of safety and anemia outcomes between the Janus kinase (JAK) inhibitors momelotinib and pacritinib in patients with myelofibrosis.

METHODS

Treatment-emergent adverse events (AEs) and anemia outcomes were compared in a pooled population of JAK inhibitor - experienced and - naive patients treated with momelotinib (SIMPLIFY-1/SIMPLIFY-2/MOMENTUM) or pacritinib (PERSIST-2/PAC203).

RESULTS

Momelotinib had statistically significantly lower odds and risk for all grades of diarrhea, nausea, peripheral edema, and vomiting as well as grade 3/4 and serious AEs vs pacritinib. Momelotinib-treated patients also had greater odds/possibility of hemoglobin improvement of ≥ 1 g/dL and clinical improvement in hemoglobin.

CONCLUSIONS

Momelotinib provides a more favorable safety profile and a higher chance for hemoglobin improvement vs pacritinib.

摘要

目的

对骨髓纤维化患者中，Janus激酶（JAK）抑制剂莫美替尼和帕可替尼的安全性及贫血相关结局进行间接治疗比较。

方法

在接受过JAK抑制剂治疗和未接受过JAK抑制剂治疗的患者合并人群中，比较接受莫美替尼（SIMPLIFY-1/SIMPLIFY-2/MOMENTUM）或帕可替尼（PERSIST-2/PAC203）治疗后出现的治疗中不良事件（AE）及贫血相关结局。

结果

与帕可替尼相比，莫美替尼在所有级别的腹泻、恶心、外周水肿和呕吐以及3/4级和严重AE方面的发生率和风险在统计学上显著更低。接受莫美替尼治疗的患者血红蛋白改善≥1 g/dL及血红蛋白临床改善的几率/可能性也更高。

结论

与帕可替尼相比，莫美替尼具有更良好的安全性，且血红蛋白改善的机会更高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/761e/12218468/48b7810ece91/IFON_A_2511562_F0004_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/761e/12218468/3e113731faa7/IFON_A_2511562_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/761e/12218468/bbe6e4bd0840/IFON_A_2511562_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/761e/12218468/a00b51743954/IFON_A_2511562_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/761e/12218468/48b7810ece91/IFON_A_2511562_F0004_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/761e/12218468/3e113731faa7/IFON_A_2511562_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/761e/12218468/bbe6e4bd0840/IFON_A_2511562_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/761e/12218468/a00b51743954/IFON_A_2511562_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/761e/12218468/48b7810ece91/IFON_A_2511562_F0004_B.jpg

相似文献

1
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis.莫洛替尼与帕西替尼治疗骨髓纤维化患者安全性及贫血转归的间接治疗比较
Future Oncol. 2025 Jul;21(16):2067-2075. doi: 10.1080/14796694.2025.2511562. Epub 2025 Jun 6.
2
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis.莫洛替尼与费德拉替尼治疗骨髓纤维化患者安全性的间接治疗比较
Future Oncol. 2025 Jul;21(16):2077-2087. doi: 10.1080/14796694.2025.2511564. Epub 2025 Jun 6.
3
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.用莫洛替尼治疗的初治或经治JAK抑制剂的骨髓纤维化患者输血强度的纵向评估
Clin Lymphoma Myeloma Leuk. 2025 Mar;25(3):199-211. doi: 10.1016/j.clml.2024.10.001. Epub 2024 Oct 16.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
7
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物：网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
10
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.莫米松替比 versus 持续芦可替尼或 JAK 抑制剂治疗经验的骨髓纤维化伴贫血患者的最佳可用治疗：SIMPLIFY-2 的亚组分析。
Adv Ther. 2024 Sep;41(9):3722-3735. doi: 10.1007/s12325-024-02928-4. Epub 2024 Jul 11.

本文引用的文献

1
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options.骨髓纤维化中贫血的治疗：聚焦新型治疗选择。
Expert Opin Investig Drugs. 2024 Jan;33(1):27-37. doi: 10.1080/13543784.2023.2294324. Epub 2024 Feb 12.
2
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.帕克里替尼是一种有效的 ACVR1 抑制剂，可显著改善骨髓纤维化患者的贫血症状。
Blood Adv. 2023 Oct 10;7(19):5835-5842. doi: 10.1182/bloodadvances.2023010151.
3
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Momelotinib 的长期安全性和生存获益：3 期随机对照临床试验的综合分析。
Blood Adv. 2023 Jul 25;7(14):3582-3591. doi: 10.1182/bloodadvances.2022009311.
4
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.莫洛替尼与达那唑治疗有症状的贫血和骨髓纤维化患者的疗效对比（MOMENTUM）：一项国际、双盲、随机、对照3期研究的结果
Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0.
5
Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 10/L): Final Analysis of an Open-Label Phase 2 Study.鲁索替尼治疗骨髓纤维化且血小板计数低（50 - 100×10⁹/L）患者的安全性和有效性：一项开放标签2期研究的最终分析
Clin Lymphoma Myeloma Leuk. 2022 May;22(5):336-346. doi: 10.1016/j.clml.2021.10.016. Epub 2021 Nov 2.
6
Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.接受 fedratinib 治疗的中危 2 或高危骨髓纤维化患者的安慰剂对照 III 期 JAKARTA 试验的更新结果。
Br J Haematol. 2021 Oct;195(2):244-248. doi: 10.1111/bjh.17727. Epub 2021 Jul 30.
7
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.确定 pacritinib 的推荐剂量：PAC203 剂量发现试验在晚期骨髓纤维化中的结果。
Blood Adv. 2020 Nov 24;4(22):5825-5835. doi: 10.1182/bloodadvances.2020003314.
8
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.帕克里替尼对比包括芦可替尼在内的最佳可用疗法治疗骨髓纤维化患者的随机临床试验。
JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818.
9
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.Momelotinib对比最佳可用疗法治疗既往接受过鲁索替尼治疗的骨髓纤维化患者（SIMPLIFY 2）：一项随机、开放标签的3期试验
Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.
10
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.SIMPLIFY-1：一项在初治的骨髓纤维化患者中比较莫洛替尼与芦可替尼的III期随机试验。
J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20.